Indication
Methotrexate toxicity
Methotrexate toxicity is an acute or chronic adverse clinical state resulting from supratherapeutic exposure to, or impaired elimination of, the antifolate antimetabolite methotrexate. Read more about Methotrexate toxicity
46 drugs 37 manufacturers
Drugs that treat it
Common Methotrexate toxicity therapies.
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonMethotrexate toxicity is an acute or chronic adverse clinical state resulting from supratherapeutic exposure to, or impaired elimination of, the antifolate antimetabolite methotrexate.
Commonly arising in patients treated for autoimmune diseases due to accidental daily rather than weekly dosing, or in oncologic populations receiving high-dose intravenous chemotherapy, it predominantly damages rapidly dividing tissues and organs responsible for drug clearance.
Pathophysiologically driven by the competitive inhibition of dihydrofolate reductase and subsequent depletion of reduced folates necessary for DNA and RNA synthesis, toxicity characteristically manifests with severe mucositis, gastrointestinal ulceration, myelosuppression presenting as pancytopenia, acute kidney injury from tubular crystalluria, and potential hepatotoxicity or pneumonitis.
- nih.gov
Methotrexate toxicity is an acute or chronic adverse clinical state resulting from supratherapeutic exposure to, or impaired elimination of, the antifolate antimetabolite methotrexate Pathophysiologically driven by the competitive inhibition of dihydrofolate reductase and subsequent depletion of reduced folates necessary for DNA and RNA synthesis, toxicity characteristically manifests with severe mucositis, gastrointestinal ulceration, myelosuppression presenting as pancytopenia, acute kidney in...
- wapc.org
Methotrexate toxicity is an acute or chronic adverse clinical state resulting from supratherapeutic exposure to, or impaired elimination of, the antifolate antimetabolite methotrexate Commonly arising in patients treated for autoimmune diseases due to accidental daily rather than weekly dosing, or in oncologic populations receiving high-dose intravenous chemotherapy, it predominantly damages rapidly dividing tissues and organs responsible for drug clearance
- nih.gov
Commonly arising in patients treated for autoimmune diseases due to accidental daily rather than weekly dosing, or in oncologic populations receiving high-dose intravenous chemotherapy, it predominantly damages rapidly dividing tissues and organs responsible for drug clearance
- nih.gov
Pathophysiologically driven by the competitive inhibition of dihydrofolate reductase and subsequent depletion of reduced folates necessary for DNA and RNA synthesis, toxicity characteristically manifests with severe mucositis, gastrointestinal ulceration, myelosuppression presenting as pancytopenia, acute kidney injury from tubular crystalluria, and potential hepatotoxicity or pneumonitis
- nih.gov
Pathophysiologically driven by the competitive inhibition of dihydrofolate reductase and subsequent depletion of reduced folates necessary for DNA and RNA synthesis, toxicity characteristically manifests with severe mucositis, gastrointestinal ulceration, myelosuppression presenting as pancytopenia, acute kidney injury from tubular crystalluria, and potential hepatotoxicity or pneumonitis
- eviq.org.au
Pathophysiologically driven by the competitive inhibition of dihydrofolate reductase and subsequent depletion of reduced folates necessary for DNA and RNA synthesis, toxicity characteristically manifests with severe mucositis, gastrointestinal ulceration, myelosuppression presenting as pancytopenia, acute kidney injury from tubular crystalluria, and potential hepatotoxicity or pneumonitis
Personalize your experience
Follow Methotrexate toxicity and get updates as they land.
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.